A Phase 3 interventional study of LX211 in Noninfectious Uveitis, sponsored by Lux Biosciences, Inc.. Completed at 52 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.
Sponsored by Lux Biosciences, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.
Among the 139 studies in Uveitis with a site in United States, this one is the 14th largest by enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2011, is one of 31 in phase 3, and was the 67th registered.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
Browse Uveitis studies →7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages up to 17
Quan Dong Nguyen · Sites in United States
Ages 18–70
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
Meyer Children's Hospital IRCCS · Sites in United States, Belgium, Greece and 2 more countries
Ages 1–16
The Cleveland Clinic · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 40 · Phase 3 31 · Phase 4 9
First in 1987; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 19 across the 100 interventional studies, 123 across the 36 observational. Of the 117 that completed or were terminated, 50 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 139 have an industry lead sponsor. The 10 most frequent:
Lux Biosciences, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Lux Biosciences, Inc. has 4 studies filed under Uveitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518134Jaeb Center for Health ResearchA Study of Uveitis in Children <18 Years of Age | 2027-04-01 |
| NCT04704609The Cleveland ClinicImaging Quantification of Inflammation (IQI) | 2027-04-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Uveitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must be:
Exclusion Criteria:
The following conditions are exclusionary if present:
Prior and Current Treatment:
- As defined in the protocol
Extraocular Conditions:
- As defined in the protocol.
Laboratory, Blood Pressure and Evaluations:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LX211
Drug: LX211
Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio: * Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d. * Treatment Arm B: placebo p.o. b.i.d. Dosage Form: • Soft gelatin capsule Duration of treatment: • 24 weeks
The change from baseline in graded vitreous haze in the study eye at 12 weeks of therapy or at the time of treatment failure, if earlier.
Time frame: 12 weeks
Daily mean systemic corticosteroid dose used during Weeks 12-24
Time frame: Weeks 12-24
Time to augmentation with corticosteroid therapy.
Time frame: Week 24
The record gives a start of Feb 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Lux Biosciences, Inc.